Brought to you by 
Catalyst licenses North American rights to BioMarin's LEMS candidate Firdapse; Japan rights added
30 May 2019
Executive Summary
BioMarin Pharmaceutical Inc. (developing treatments for rare diseases) has granted specialty pharmaco Catalyst Pharmaceutical Partners Inc. exclusive rights to develop and sell the autoimmune disease therapy Firdapse (amifampridine) in North America.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Catalyst licenses North American rights to BioMarin's LEMS candidate Firdapse; Japan rights added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice